Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 6Recruiting 2Withdrawn 1Completed 1

Sponsor Class

OTHER 27INDUSTRY 23NIH 2OTHER_GOV 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Gynecologic 1

Conditions

Ovarian Neoplasms 1Neoplasm Metastasis 1Malignant Female Reproductive System Neoplasm 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1

Interventions

Specimen Handling 116Magnetic Resonance Spectroscopy 78Biopsy 69Cyclophosphamide 24pembrolizumab 22Cisplatin 21fludarabine 18Platinum 171,2-diaminocyclohexaneplatinum II citrate 17Taxes 16Paclitaxel 16Carboplatin 16Nivolumab 15Immunoglobulin G 14Disulfides 14X-Rays 13Radiation 13Doxorubicin 12venetoclax 11Radiotherapy 11Gemcitabine 11durvalumab 9cabozantinib 8aldesleukin 8Prednisone 8atezolizumab 7Cytarabine 7olaparib 6lutetium Lu 177 dotatate 6gallium Ga 68 dotatate 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × NIH × palbociclib × Clear all
NCT05564377 2026-06-02

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
2,900 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT06126276 2026-06-02

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
70 enrolled
Other solid neoplasm

Malignant Female Reproductive System Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡